The Liquor and Cannabis Board (LCB) announced recently that outgoing Governor Jay Inslee has appointed Jim Vollendroff, MPA, as chair of the LCB board.

Jim Vollendroff, MPA.

Chair Vollendroff will fulfill former Chair David Postman’s term which concludes in Jan. 2027. Postman vacated the board chair position recently to serve as chief of staff for incoming Attorney General Nick Brown. Prior to his appointment, Chair Vollendroff has served as a board member since 2022.

“I am grateful for the opportunity. Together with Board Member Ollie Garrett, I look forward to continuing the board’s work in my new role as chair, said Vollendroff. “I want to thank former Chair David Postman for his years of leadership. I am eager to work with my fellow board members and LCB staff addressing emerging trends within the dynamic industries we license and regulate.”
Continue reading

For the second straight month, marijuana sales in Missouri broke the previous monthly record.

There was $130.51 million worth of marijuana and marijuana products sold legally in Missouri in December, breaking the previous record of $128 million set the prior month. This brings 2024’s total to $1.36 billion, and the all-time total to $3.4 billion.

A large majority of December’s marijuana sales were recreational purchases, accounting for $115.47 million. In contrast, medical marijuana patients purchased $15.04 million in product in December.
Continue reading

Today, the Missouri Department of Health and Senior Services (DHSS) announced that it has transferred $5,459,172 in funds generated by Missouri’s adult use marijuana program to agencies as outlined in Article XIV, Section 2, of the Missouri Constitution, including the Missouri Veterans Commission.

This brings the total amount transferred from funds generated by Missouri’s adult use marijuana program this fiscal year to $21,836,688, and that total has been distributed to recipient agencies of adult use program funds as follows:
Continue reading

Tilray Medical, a division of Tilray Brands, Inc., announced today that its German subsidiary, Tilray Deutschland GmbH, has secured a tender to supply Luxembourg with its cannabis flower.

The granting of this tender by the Ministry of Health and Social Security for the Grand Duchy of Luxembourg “highlights the trust placed in Tilray Medical to deliver high-quality medical cannabis on a consistent basis across the global medical cannabis industry”, states a press release sent this morning. Additionally, “it reinforces Tilray’s commitment to deliver on Europe’s growing demand for premium medical cannabis products.”

Denise Faltischek, Chief Strategy Officer and Head of International, said, “We are honored to have been selected again to supply medical cannabis to Luxembourg. This is a testament to the unwavering dedication of our team in providing patients around the world with high-quality medical cannabis products.”
Continue reading

Arizona’s marijuana market continues to thrive, with total sales in 2024 reaching an impressive $1,212,271,008.

The year concluded with $91 million in sales recorded for December, while March stood out as the top month, bringing in $127 million, according to the research firm Headset. The $1.2 billion in marijuana sales in 2024 resulted in nearly $300 million in tax revenue for the state, according to the Arizona Department of Revenue.

Recreational marijuana sales in Arizona began after voters approved Proposition 207 in November 2020. This measure legalized marijuana for those aged 21 and older, allowing the purchase of up to one ounce of marijuana and up to five grams of concentrates from licensed marijuana retail outlets and dispensaries.
Continue reading

The long-awaited public hearing on marijuana rescheduling will begin on January 21, according to an order issued last month by a Drug Enforcement Administration (DEA) administrative law judge.

The hearings will feature arguments from the DEA, proponents of rescheduling, and designated opposition groups, with sessions scheduled to continue into early March, covering a 6-week period. The hearings will be focused on the DEA’s proposal to move marijuana from its current status as a Schedule I drug, making it illegal for all purposes, to the less restrictive Schedule III.

The hearings will follow this schedule:
Continue reading